**FULL PAPER  Virology**

**Construction of an Expression System for Bioactive IL-18 and Generation of Recombinant Canine Distemper Virus Expressing IL-18**

Yuxiu LIU1,2, Hiroki SATO1*, Masahiro HAMANA1, Navita Anisia MOONAN1, Misako YONEDA1, Xianzhu XIA2 and Chieko KAI1

1)Laboratory Animal Research Center, Institute of Medical Science, The University of Tokyo, 4–6–1 Shirokanedai, Minato-ku, Tokyo 108–8639, Japan
2)College of Veterinary Medicine, Agricultural Division, Jilin University, Changchun 130062, China

(Received 4 April 2014/Accepted 22 May 2014/Published online in J-STAGE 4 June 2014)

**ABSTRACT.** Interleukin 18 (IL-18) plays an important role in the T-helper-cell type 1 immune response against intracellular parasites, bacteria and viral infections. It has been widely used as an adjuvant for vaccines and as an anticancer agent. However, IL-18 protein lacks a typical signal sequence and requires cleavage into its mature active form by caspase 1. In this study, we constructed mammalian expression vectors carrying cDNA encoding mature canine IL-18 (cIL-18) or mouse IL-18 (mIL-18) fused to the human IL-2 (hIL-2) signal sequence. The expressed proIL-18 proteins were processed to their mature forms in the cells. The supernatants of cells transfected with these plasmids induced high interferon-γ production in canine peripheral blood mononuclear cells or mouse splenocytes, respectively, indicating the secretion of bioactive IL-18. Using reverse genetics, we also generated a recombinant canine distemper virus that expresses cIL-18 or mIL-18 fused to the hIL-2 signal sequence. As expected, both recombinant viruses produced mature IL-18 in the infected cells, which secreted bioactive IL-18. These results indicate that the signal sequence from hIL-2 is suitable for the secretion of mature IL-18. These recombinant viruses can also potentially be used as immunoadjuvants and agents for anticancer therapies in vivo.

**KEYWORDS:** canine distemper virus, interferon-γ, interleukin 18

---

Canine distemper virus (CDV) is an enveloped, negative-sense, single-stranded RNA virus of the genus *Morbillivirus* in the family *Paramyxoviridae*, which causes a highly contagious and fatal multisystemic infection in domestic and wild carnivores [26]. CDV has ideal features for a live vaccine, because it not only induces an innate immune response, but also induces an adaptive immune response, which elicits life-long immunity in animals. In the 1950s, live attenuated CDV vaccines were introduced to prevent and reduce the incidence of canine distemper (CD) in susceptible animals. However, severe clinical CD outbreaks in immunized dogs have recently been documented [4, 16, 21]. Therefore, it is very important to improve the effects of the current vaccine. The production of highly neutralizing antibodies has always been used as a substitute marker to evaluate the immunogenicity and protective capacity of CDV vaccines, however, the induction of cell-mediated immunity has also been shown to be important for successful vaccination [1, 11, 15, 31].

IFN-γ is an important activator of macrophages and is critical for innate and adaptive immunity against viral and intracellular bacterial infections and for tumor control. IFN-γ is produced by NK cells and by natural killer T cells, CD4+ Th1 cells and CD8+ cytotoxic T lymphocytes, once antigen-specific immunity develops [33]. IL-12 and IL-18 are potent activators of IFN-γ production in NK and T cells and promote the development of T-helper type 1 responses [8, 39]. IL-12 has been extensively tested for its adjuvant activity. Increasing the dose of recombinant human IL-12 in a human cytomegalovirus (CMV) vaccine increased the anti-CMV gB IgG titer and CMV-specific CD4+ T-cell proliferation [17]. DNA expressing IL-12 has also been shown to be an effective adjuvant for the simian immunodeficiency virus gag pDNA vaccine in rhesus macaques [32]. However, IL-12 is encoded by 2 separate genes, *IL12A* (p35) and *IL12B* (p40), requiring it to be cloned and expressed as 2 separate subunits in an *in vitro* study. It has been reported that IL-18 can also augment the IFN-γ-inducing capacity and antitumor activity independently of IL-12 [12]. To date, IL-18 has been used as a vaccine adjuvant and enhanced vaccine efficiency in mouse, cats, pigs and other mammals [20, 25, 28].

IL-18 is synthesized as a biologically inactive precursor protein (proIL-18, 22 kDa) by cells of the immune system and other types of cells [12]. ProIL-18 lacks a typical signal sequence for secretion [27] and is processed into its mature active form (mature IL-18, 18 kDa) by caspase-1 cleavage. Without the caspase-1 cleavage process, the mature IL-18 protein cannot be efficiently secreted across the cell membrane. Several reports have indicated that the addition of a signal sequence derived from various secreted proteins enhances the extracellular secretion of bioactive IL-18 [14, 24, 29]. It has been reported that the fusion of the canine IL12-p40 signal sequence (cIL-12p40ss) to mature canine IL-18 (cIL-18) enhanced the secretion efficiency of bioac-
toxic IL-18 [37].

In the present study, we compared the secretion efficiency of signal sequence for bioactive cIL-18. We also generated a recombinant CDV (rCDV) expressing mature IL-18 as a new potential candidate vaccine adjuvant or anticancer reagent [34]. Interestingly, a recent study demonstrated that rCDV expressing rabies virus (RABV) G protein (RV-G) protected both dogs and mice against RABV challenge [39], even though mice are not a susceptible natural host of CDV. Therefore, we also tested mouse IL-18 in a similar manner.

MATERIALS AND METHODS

Cells and viruses: B95a (marmoset lymphoblastoid) cells [19] were maintained in RPMI 1640 medium (Gibco, Carlsbad, CA, U.S.A.), and HEK293 and 293T cells were cultured in Dulbecco’s modified Eagle’s medium (Sigma, St. Louis, MO, U.S.A.) supplemented with 5% FCS (Sigma), 100 U/ml penicillin G and 100 μg/ml streptomycin (Invitrogen, Carlsbad, CA, U.S.A.). The Yanaka strain of CDV [10] and the rCDVs were cultured with B95a cells in RPMI 1640 medium supplemented with 2% FCS. Canine PBMCs were isolated were reverse transcribed with SuperScript II Reverse Transcriptase (Invitrogen) and a random 6-mer primer. To construct a mammalian expression plasmid encoding the entire cIL-18, the full-length cIL-18 cDNA was amplified by PCR using canine PBMC cDNA, LA-Taq DNA polymerase (TaKaRa, Otsu, Japan) and a primer pair with SacI restriction sites (SacI-cIL18 F and SacI-cIL18 R, Table 1). This was then inserted into the pCAGGS mammalian expression vector to generate pCAG–cIL18. To construct a mammalian expression plasmid encoding mature cIL-18 fused to the cIL12-p40 signal sequence, the cIL12-p40 cDNA was amplified by PCR from canine PBMC cDNA with a primer pair with AflII and KpnI restriction sites (AflII-cIL12p40 F and KpnI-cIL12p40 R, Table 1) and inserted into the pCAGGS vector, generating pCAG–cIL12p40. The cDNA of mature cIL-18, encoding amino acids 37–193, was amplified by PCR using a primer pair with Ndel and KpnI restriction sites (Ndel-mature-cIL18F and KpnI-mature-cIL18R, Table 1). pCAG–cIL12p40 was digested with Ndel immediately downstream from the cIL12-p40 signal sequence, and with KpnI, and then introduced the mature cIL-18 cDNA digested with Ndel and KpnI, generating pCAG–cIL12ss–cIL-18.

To construct a mammalian expression plasmid encoding mature cIL-18 or mIL-18 fused to the human IL-2 signal sequence, cDNA encoding mature cIL-18 or mature mIL-18 (amino acids 36–192) was amplified by PCR from canine PBMC cDNA with a primer pair with NcoI and BglII restriction sites (NcoI-cIL18 F and BglII-cIL18 R, Table 1). The cDNAs were digested with NcoI and BglII and inserted into the restriction sites in the eukaryotic expression vector pFUSE–hL2ss–Fc2 (InvivoGen, San Diego, CA, U.S.A.), which contains the hIL-2 signal sequence for the secretion of fused proteins, generating pFuse–hL2ss–cIL-18 and pFuse–hL2ss–mIL-18.

Generation of rabbit polyclonal antibody against cIL-18: The cDNA of cIL-18 was cloned into pET42 (b) E. coli expression vector (Novagen, Darmstadt, Germany) in frame with C-terminal of glutathione-s-transferase (GST) (pET42-cIL18). A 1-liter culture of E. coli (BL21 strain) transformed

---

Table 1. Primers used for PCR amplification

| Name                | Primer sequences                                      |
|---------------------|-------------------------------------------------------|
| SacI-cIL18 F        | 5’-GAGCTCATGCTGCTAATACCTAATAGGAAG-3’                 |
| SacI-cIL18 R        | 5’-GAGCTCATAGCTAGCTTCAGGTTGTGCTG-3’                  |
| AflII-cIL12p40 F    | 5’-CTCTAACGATTCATCTTCAGGC-3’                         |
| AflII-cIL12p40 R    | 5’-GGTACCCTAGCC-3’                                    |
| Ndel-mature-cIL18 F | 5’-GCATATGGATTTTGGCAACGTTGAACTAAAC-3’                |
| KpnI-mature-cIL18 R | 5’-GCTAGCTCTTGTTTTGAACAGTG-3’                        |
| Ncol-mature-cIL18 F | 5’-CATGCTAATTGCGAC-3’                                 |
| BglI-mature-cIL18 R | 5’-AGATCTGCTAATTGCGAC-3’                             |
| BglI-mature-mIL18 F | 5’-ATAAGCCATGCTACCTTGCGAC-3’                         |
| FseI-cIL18-CDV F    | 5’-GGCCGCCGCTAACTCTTTAATACTTACTGGCGACG-3’            |
| FseI-cIL18-CDV R    | 5’-GGCCGCCGCTAACTCTTTAATACTTACTGGCGACG-3’            |
| FseI-hIL2s-CDV F    | 5’-GGCCGCCGCTAACTCTTTAATACTTACTGGCGACG-3’            |
| FseI-hIL2s-CDV R    | 5’-GGCCGCCGCTAACTCTTTAATACTTACTGGCGACG-3’            |
| CDV-N F             | 5’-TTGTTGTTGATAGCCGAATTCACGCGGAC-3’                  |
| CDV-N R             | 5’-CCCTCGATGGGATTTTACGAGGTTGGTAC-3’                  |

Restriction sites are underlined. CDV transcription signal unit sequences are described in lowercase letters.
with pET2-cIL18 was incubated at 37°C. When the optical
density at 600 nm (OD₆₀₀) reached 0.4, expression of the
recombinant protein was induced by the addition of 1 mM
isopropyl-β-D-thiogalactopyranoside. After a 4-hr incuba-
tion, the E. coli was washed with PBS, suspended with
sonication buffer (0.5% Triton X-100, 50 mM Tris-HCl [pH
8.0], 1 mM EDTA and 10 mM dithiothreitol) and sonicated
with Sonifier450 (Branson, North Olmsted, OH, U.S.A.)
for 5 min on ice. The lysate was incubated with 0.2 mg/ml
lysozyme (Wako, Osaka, Japan), 10 µg/ml DNase I (Roche,
Mannheim, Germany) and 1 mM MgCl₂ for 45 min at room
temperature. The lysate was added with 7 mM EDTA, incu-
bated for 30 min at 37°C and then centrifugation at 12,000
× g for 20 min. The pellet containing purified inclusion bod-
cies of GST-cIL18 fusion protein (2.5 mg) was mixed
with complete Freund’s adjuvant (Difco, Sparks, MD, U.S.A.)
and immunized into rabbit. After 2 weeks, the rabbit was
immunized with 2.5 mg of GST-cIL18 mixed with incomplete
Freund’s adjuvant (Difco). After 2 weeks, the serum was col-
lected. The specificity of the antiserum against cIL-18 was
confirmed by immunoblotting analysis. Briefly, the lysates were separated
with 12% SDS-PAGE, and the separated proteins were trans-
ferred onto an Immobilon-P membrane (Millipore, Billerica,
MA, U.S.A.). The membrane was blocked with Block ACE
reagent (DS Pharma Biomedical, Osaka, Japan) and then in-
cubated with rabbit anti-cIL-18 antibody, rabbit anti-mIL-18
antibody (Invitrogen) or mouse anti-glyceraldehyde-3-phos-
phate dehydrogenase (GAPDH) monoclonal antibody (GE
Healthcare) overnight at 4°C. The membrane was washed
3 times with 0.05% Tween-PBS and incubated with a
1:2,000 dilution of horseradish-peroxidase-conjugated goat
anti-rabbit immunoglobulin antibody or rabbit anti-mouse
immunoglobulin antibody (Dako Cytomation, Glostrup,
Denmark) for 1 hr at 37°C. The immunoreactive bands
were detected with ECL Prime Western Blotting Detection
Reagent (GE Healthcare). Chemiluminescence was scanned
with a luminescent image analyzer (LAS-1000UV Minisys-
tem; Fujifilm, Tokyo, Japan).

Recovery of recombinant viruses: To generate rCDV,
we used reverse genetics to recover the recombinant virus
previously established in Paramyxovirus [3, 23]. Plasmid
pCDV containing the full-length cDNA of the RNA genome
of the CDV Yanaka strain was constructed previously [10].
The entire coding region of cIL-18, hIL-2ss–cIL-18 and
hIL-2ss–mIL-18 was amplified with primer pairs containing
the 50% tissue culture infective dose (TCID50) determined with the limiting dilution method and expressed as later. The viruses were harvested, and their titers were determined with Isogen reagent and reverse transcribed. PCR amplification was performed using the N gene primers (CDV-N F and CDV-N R, Table 1) pre-


compiled from 293T cells transfected with the mammalian expression plasmids or B95a cells infected with CDVs were added to 10^6 canine PBMCs in 100 µl of culture medium in a 96-well plate. After 48 hr, the supernatant from each well was examined for canine IFN-γ with an ELISA (Quantikine Canine IFN-γ Immunoassay; R&D Systems, Minneapolis, MN, U.S.A.), according to the manufacturer’s instructions. Alternatively, 50 µl of the supernatant was added to 10^6 mouse spleen cells in 50 µl of culture medium. After 48 hr, IFN-γ secretion was detected with the Mouse IFN-gamma ELISpot Kit (R&D Systems), and the frequency of mouse IFN-γ-secreting cells was quantified according to the manufacturer’s instructions.

RESULTS

Bioactivity of recombinant IL-18 with different signal sequences in mammalian cells: First, we compared the secretion efficiency of the signal sequence with that of mature cIL-18. 293T cells were transfected with recombinant plasmids encoding entire cIL-18 (pCAG-cIL18) or mature cIL-18 fused to the cIL-12 signal sequence (pCAG-cIL12ss-cIL18) or to the human IL-2 signal sequence (pFuse-hIL2ss-cIL18) (Fig. 1A). The expression of cIL-18 protein in the cells was detected with an immunoblotting analysis. The proIL-18 (22 kDa) protein was detected in all the transfected cells, whereas mature cIL-18 (18 kDa) was detected in the cells transfected with pCAG-cIL12ss-cIL18 or pFuse-hIL2ss-cIL18, but not in cells transfected with pCAG-cIL18 (Fig. 1B).

To examine the bioactivity of the cIL-18 secreted from the transfected cells, the culture supernatant was cocultured with canine PBMCs, and the amount of canine IFN-γ produced by the PBMCs was measured. The supernatants of the cells expressing entire cIL-18 induced little IFN-γ production when compared with the control, whereas the supernatants of cells expressing cIL-12ss-cIL-18 slightly enhanced the induction efficiency, as in the previous report [37]. Interestingly, the supernatant of cells transfected with pFuse-hIL2ss-cIL18 induced significant IFN-γ production (Fig. 2A). This result suggests that the human IL-2 signal sequence is more effective for expressing mature IL-18 in vitro than the canine IL-12-p40 signal sequence. We then used hIL-2ss to express bioactive mouse IL-18 (Fig. 1A). We only detected mature mIL-18 in the pFuse-hIL2ss-mIL18 transfected cells (Fig. 1B). The supernatant from cells transfected with this plasmid also effectively stimulated mouse spleen cells to secrete IFN-γ (Fig. 2B). These results indicate that the human IL-2 signal sequence is suitable for the secretion of bioactive IL-18 protein from cells.

Generation of rCDVs expressing canine or mouse IL-18: To generate rCDVs expressing IL-18, we constructed CDV full-genome plasmids containing cDNA encoding the entire cIL-18, hIL-2ss-cIL-18 or hIL-2ss-mIL-18 sequence (Fig. 3A). The rCDVs were rescued from the plasmids as de-
scribed in the Methods section, and we successfully generated the rCDVs. The expression of mRNA from the inserted gene in each viral genome was confirmed by RT-PCR (Fig. 3B). To identify the IL-18 proteins expressed by the viruses, infected B95a cells were subjected to an immunoblotting analysis. Two bands corresponding to proIL-18 and mature IL-18 were detected (Fig. 3C), and each sample showed a similar band pattern, corresponding to that of the mammalian expression plasmids (Fig. 1B).

We then examined the growth kinetics of the rCDVs. As shown in Fig. 4, all the recombinant viruses showed slightly higher peaks for cell-associated virus than for released virus, and the maximum titers were similar to that of the parental Yanaka strain (Fig. 4). These results demonstrate that in B95a cells, IL18 inserted into the CDV genome and expressed from recombinant viruses had no obvious effect on viral replication or growth kinetics.

Bioactivity of IL-18 produced by rCDV: To investigate whether the mature IL-18 protein expressed by rCDV was bioactive, we harvested the supernatants of the virus-infected cells and cocultured them with canine PBMCs. The supernatant contained infectious CDV released from the cells, but the parental CDV induced little IFN-γ production in the PBMCs (Fig. 5A) because CDV infection of canine PBMCs is inefficient [10]. The supernatant from the rCDV–cIL18-infected cells induced slight IFN-γ production, and
as expected, rCDV–hIL2ss–cIL18 induced significant IFN-γ production (Fig. 5A). Similarly, the supernatant from rCDV–hIL2ss–mIL18-infected cells also stimulated mouse spleen cells and induced IFN-γ production (Fig. 5B). The increased IFN-γ expression in PBMCs and splenocytes confirmed the biological activity of IL-18 secreted by rCDV–hIL2ss–cIL18- and rCDV–hIL2ss–mIL18-infected cells.

DISCUSSION

Based on its biological activity, IL-18 has been widely used as a vaccine adjuvant for infectious diseases [5, 6, 12, 18]. Various expression systems and cytokine signal peptides have been used to express bioactive IL-18. For example, feline IL-18 fused to human immunoglobulin κ was constructed as a DNA vaccine adjuvant and enhanced the efficacy of a feline leukemia virus DNA vaccine [14]. The signal sequence from the human IL-1β receptor antagonist protein fused to mature feline or equine IL-18 induced IFN-γ production in a KG-1 assay [24]. Porcine IL-18 fused to the baculovirus gp67-encoded signal sequence displayed bioactivity in a baculovirus system [22]. In the present study, we evaluated the utility of the human IL-2 signal sequence and demonstrated that it is more efficient than the previously reported canine IL12-p40 signal sequence [37] and that it can be used to express both canine and mouse IL-18.

The human IL-2 signal sequence contains 21 amino acids and shares the common characteristics of the signal peptides of other secretory proteins. Intracellular cleavage of the IL-2 signal peptide occurs after Ser20 and leads to the secretion of the antigenic protein. The signal sequences of canine and mouse IL-2 also consist of 20 amino acids, whereas the homology of the canine IL-2 signal sequence with that of the human sequence is 80% and that of the mouse IL-2 signal sequence is only 60%. Meanwhile, the human IL-2 signal sequence derived from the plasmid we used, pFuse–hlgG2–Fc2, can function in a variety of commonly used mammalian cells, from human cells to Chinese hamster cells. Therefore, rCDV–hIL2ss–cIL18 and rCDV–hIL2ss–mIL18 can secrete functional IL-18 after undergoing the proper processing in an appropriate host. The difference in the intracellular pro-
cessing efficiency of cIL-18 and mIL-18 (Figs. 1B and 3C) may be attributable to their respective primary sequences immediately downstream from the cleavage site (cIL-18: 37-YFGKLEPKLS, mIL-18: 36-NFGRHLCTTTA). We will also examine the secretion efficiencies of cIL-18 and mIL-18 at protein level using ELISA in the future.

To date, divalent vaccines based on several recombinant viruses that encode CDV glycoproteins (hemagglutinin [H] and fusion [F]) have been investigated to protect against CDV and other pathogens. For example, vaccines based on recombinant vaccinia viruses or canarypox vectors engineered to express CDV glycoproteins have been tested in dogs and ferrets [30, 35]. These vaccines elicited protective immune responses, but it has yet to be determined whether the duration of these immune responses is equivalent to that of the responses induced with conventional live CDV vaccines [2]. It has been reported that 2 replication-competent vaccines [2] of the responses induced with conventional live CDV vaccines are easily neutralized by CDV H and F antigens, protected dogs against CDV challenge [9]. It is well known that CAV2 vaccines are easily recovered from the respiratory tracts of sentinel dogs [7].

In the case of CDV, live attenuated vaccines are known to confer long-lasting immunity, and recombination of the CDV genome is impossible during the viral replication cycle. Therefore, the development of CDV-based multivalent vaccines is the most appropriate approach to the development of vaccines against CDV and other pathogens. A recent study demonstrated that an attenuated rCDV vaccine strain expressing RV-G conferred protective immunity against challenge with RABV in mice and dogs, providing particularly effective protection for more than a year in dogs [40]. This result confirms that CDV is a suitable vaccine vector.

Many recent studies have indicated that IL-18 plays an important role not only in host defenses against pathogens but also in immunotherapies for cancer [reviewed in 34]. Oncolytic virotherapy has been used as a novel strategy for cancer treatment. Interestingly, previous reports have shown that CDV and measles virus (MV), a human Morbillivirus, have oncolytic activity. CDV was shown to infect lymphoblasts isolated from canine lymphoma patients, leading to cell death by apoptosis [38]. In our previous study, we also demonstrated that recombinant MV, which was mutated so that it could not bind to the lymphoid-cell receptor SLAM, showed oncolytic activity against breast cancer in vivo [36]. Extrapolating from these data, we surmise that application of rCDV–hIL2ss–cIL18 plays a positive role in the cancer therapy using oncolytic activity of CDV.

In conclusion, we constructed an efficient secretion system of cIL-18 and succeeded in generating rCDV expressing bioactive IL-18. The recombinant CDV, rCDV–hIL2ss–cIL18, could offer a new approach to investigating the role of IL-18 in the host defense mechanism, the pathogenesis of infectious diseases and the treatment of cancer in the host.

ACKNOWLEDGMENTS. This work was supported by Grants-in-Aid for Scientific Research (KAKENHI) from the Japan Society for the Promotion of Science (JSPS) and by the Global COE Program Center of Education and Research for Advanced Genome-Based Medicine: for Personalized Medicine and the Control of Worldwide Infectious Diseases (Ministry of Education, Culture, Sports, Science and Technology, Japan).

REFERENCES

1. Appel, M. J. G., Shek, W. R., Shesheradaran, H. and Norrby, E. 1984. Measles virus and inactivated canine distemper virus induce incomplete immunity to canine distemper. Arch. Virol. 82: 73–82. [Medline] [CrossRef]
2. Barrett, T. 1999. Morbillivirus infection, with special emphasis on morbilliviruses of carnivores. Vet. Microbiol. 69: 3–13. [Medline] [CrossRef]
3. Billeter, M. A., Naim, H. Y. and Udem, S. A. 2009. Reverse genetics of measles virus and resulting multivalent recombinant vaccines: applications of recombinant measles viruses. Curr. Top. Microbiol. Immunol. 329: 129–162. [Medline] [CrossRef]
4. Blixenkrone-Moller, M., Svansson, V., Have, P., Orvell, C., Appel, M., Pedersen, I. R., Dietz, H. H. and Henriksen, P. 1993. Studies on manifestations of canine distemper virus infection in an urban dog population. Vet. Microbiol. 37: 163–173. [Medline] [CrossRef]
5. Bohn, E., Sing, A., Zumbihl, R., Bliefsfeldt, C., Okamura, H., Kurimoto, M., Heesemann, J. and Autenrieth, I. B. 1998. IL-18 (IFN-gamma-inducing factor) regulates early cytokine production in, and promotes resolution of, bacterial infection in mice. J. Immunol. 160: 299–307. [Medline]
6. Brummer, E. 1998–1999. Human defenses against Cryptococcus neoformans: An update. Mycopathologia 143: 121–125. [Medline] [CrossRef]
7. Curtis, R., Emmett, J. E. and Furminger, I. G. 1978. The pathogenicity of an attenuated strain of canine adenovirus type 2 (CAV2). Vet. Rec. 103: 380–381. [Medline] [CrossRef]
8. Dinarello, C.A., Novick, N., Puren, A.J., Fantuzzi, G., Shapiro, L., Mu’thl, H., Yoon, D.Y., Reznikov, L.L., Kim, S.H. and Rubinstein, M. 1998. Overview of interleukin-18: more than an interferon-g inducing factor. J. Leukoc. Biol. 63: 658–664. [Medline]
9. Fischer, L., Tronel, J. P., Pardo-David, C., Tanner, P., Colombet, G., Minke, J. and Audonnet, J. C. 2002. Vaccination of puppies born to immune dams with a canine adenovirus based vaccine protects against a canine distemper virus challenge. Vaccine 20: 3485–3497. [Medline] [CrossRef]
10. Fujita, K., Miura, R., Yoned, M., Shimizu, F., Sato, H., Muto, Y., Endo, Y., Tsukiyama-Kohara, K. and Kai, C. 2007. Host range and receptor utilization of canine distemper virus analyzed by recombinant viruses: Involvement of heparin-like molecule in CDV infection. Virology 359: 324–335. [Medline] [CrossRef]
11. Ghosh, S., Walker, J. and Jackson, D. C. 2001. Identification of canine helper T-cell epitopes from the fusion protein of canine distemper virus. Immunology 104: 58–66. [Medline] [CrossRef]
12. Gracie, J. A., Robertson, S. E. and McInnes, I. B. 2003. Interleukin-18. J. Leukoc. Biol. 73: 213–224. [Medline] [CrossRef]
13. Hagiwara, K., Sato, H., Inoue, Y., Watanabe, A., Yoneda, M., Ikeda, F., Fujita, K., Fukuda, H., Takamura, C., Kozuka-Hata, H., Oyama, M., Sugano, S., Ohmi, S. and Kai, C. 2008. Phosphorylation of measles virus nucleoprotein upregulates the transcriptional activity of minigenomic RNA. Proteomics 8: 1871–1879. [Medline] [CrossRef]
14. Hanlon, L., Argyle, D., Bain, D., Nicolson, L., Dunham, S., Golder, M. C., McDonald, M., McGillivray, C., Jarrett, O., Neil, J. C. and Onions, D. E. 2001. Feline Leukemia Virus DNA
Vaccine Efficacy Is Enhanced by Coadministraton with Interleukin-12 (IL-12) and IL-18 Expression Vectors. J. Virol. 75: 8424–8433. [Medline] [CrossRef]

15. Hirama, K., Takashi, K., Wakasa, C., Yoneda, M., Nishi, T., Endo, Y., Miura, R., Tsukiyama-kohara, K. and Kai, C. 2003. Cytotoxic T-lymphocyte activity specific for hemagglutinin (H) protein of canine distemper virus in dogs. J. Vet. Med. Sci. 65: 109–112. [Medline] [CrossRef]

16. Iwatsuki, K., Tokiyoshi, S., Hirayama, N., Nakamura, K., Ohashi, K., Wakasa, C., Mikami, T. and Kai, C. 2000. Antigenic differences in the H proteins of canine distemper viruses. Vet. Microbiol. 71: 281–286. [Medline] [CrossRef]

17. Jacobson, M. A., Sinclair, E., Bredt, B., Aggriplo, L., Black, D., Epling, C. L., Carvidi, A., Ho, T., Bains, R., Girling, V. and Adler, S. P. 2006. Safety and Immunogenicity of Towne Cyto megalovirus Vaccine with or without Adjuvant Recombinant Interleukin-12. Faccine 24: 5311–5319. [Medline] [CrossRef]

18. Kobayashi, K., Kai, M., Gidoh, M., Nakata, N., Endoh, M., Singh, R. P., Kasama, T. and Saito, H. 1998. The possible role of interleukin (IL)-12 and interferon-gamma-inducing factor/IL-18 in protection against experimental Mycobacterium leprae infection in mice. Clin. Immunol. Immunopathol. 88: 226–231. [Medline] [CrossRef]

19. Kobune, F., Sakata, H. and Sugiyama, A. 1999. Marmoset lymphoblastoid cells as a sensitive host for isolation of measles virus. J. Virol. 64: 700–705. [Medline]

20. Kong, N., Wang, X. H., Zhao, J. W., Hu, J. D., Zhang, H. and Zhao, H. K. 2011. A recombinant baculovirus expressing VP2 protein of infectious bursal disease virus (IBDV) and chicken Interleukin-18 (CHIIL-18) protein protects against very virulent IBDV. J. Anim. Vet. Adv. 10: 2706–2715.

21. Latha, D., Srinivasan, S. R., Thirunavukkarasu, P. S., Gunasel, L., Ramadass, P. and Narayanan, R. B. 2007. Assessment of canine distemper virus infection in vaccinated and unvaccinated dogs. Indian J. Biotechnol. 6: 35–40.

22. Muneta, Y., Morii, Y., Shimoji, Y. and Yokomizo, Y. 2000. Porcine interleukin 18: cloning, characterization of the cDNA and expression with the baculovirus system. Cytokine 12: 566–572. [Medline] [CrossRef]

23. Nagai, Y. 1999. Paramyxovirus replication and pathogenesis. Reverse genetics transforms understanding. Rev. Med. Virol. 9: 83–99. [Medline] [CrossRef]

24. O’Donovan, L. H., McMonagle, E. L., Taylor, S., Argyle, D. J. and Nicolson, L. 2004. Bioactivity and secretion of interleukin-18 (IL-18) generated by equine and feline IL-18 expression vectors. Vet. Immunol. Immunopathol. 102: 421–428. [Medline] [CrossRef]

25. O’Donovan, L. H., McMonagle, E. L., Taylor, S., Bain, D., Pacifici, A. M., Goldner, M. C., McDonald, M., Hanlon, L., Onions, D. E., Argyle, D. J., Jarrett, O. and Nicolson, L. 2005. A vector expressing feline mature IL-18 fused to IL-1 antagonist protein signal sequence is an effective adjuvant to a DNA vaccine for feline leukaemia virus. Vaccine 23: 3814–3823. [Medline] [CrossRef]

26. Ohishi, K., Ando, A., Suzuki, R., Takishita, K., Kawato, M., Katsumata, E., Ohtsu, D., Okutsu, K., Tokutake, K., Miyahara, H., Nakamura, H., Murayama, T. and Murayama, T. 2010. Host-virus specificity of morbilliviruses predicted by structural modeling of the marine mammal SLAM, a receptor. Comp. Immunol. Microbiol. Infect. Dis. 33: 227–241. [Medline] [CrossRef]

27. Okamura, H., Tsutsi, H., Komatsu, T., Yutsudo, M., Hakura, A., Tanimoto, T., Torigoe, K., Okura, T., Nakada, Y., Hattori, K., Akita, K., Namba, M., Tanabe, F., Konishi, K., Fukuda, S. and Kurimoto, M. 1995. Cloning of a new cytokine that induces IFN-gamma production by T cells. Nature 378: 88–91. [Medline] [CrossRef]

28. Okano, F., Satoh, M., Ido, T. and Yamada, K. 1999. Cloning of cDNA for Canine Interleukin-18 and Canine Interleukin-1beta Converting Enzyme and Expression of Canine Interleukin-18. J. Interferon Cytokine Res. 19: 27–32. [Medline] [CrossRef]

29. Osaki, T., Hashimoto, W., Gambotto, A., Okamura, H., Robbins, P. D., Kurimoto, M., Lotze, M. T. and Tahara, H. 1999. Potent antitumor effects mediated by local expression of the mature form of the interferon-gamma inducing factor, interleukin-18 (IL-18). Gene Ther. 6: 808–815. [Medline] [CrossRef]

30. Pardo, M. C., Bauman, J. E. and Mackowiak, M. 1997. Protection of dogs against canine distemper by vaccination with a canarypox virus recombinant expressing canine distemper virus fusion and hemagglutinin glycoproteins. Am. J. Vet. Res. 58: 833–836. [Medline]

31. Salerno-Gonzalves, R. and Sztein, M. B. 2006. Cell-mediated immunity and the challenges for vaccine development. Trends Microbiol. 14: 536–542. [Medline] [CrossRef]

32. Schadeck, E. B., Sidhu, M., Egan, M. A., Chong, S. Y., Piacente, P., Masood, A., Garcia-Hand, D., Cappello, S., Roopchand, V., Megati, S., Quiroz, J., Boyer, J. D., Felber, B. K., Pavlakis, G. N., Weine, D. B., Eldridge, J. H. and Israel, Z. R. 2006. A dose sparing effect by plasmid encoded IL-12 adjuvant on a SIV gag-plasmid DNA vaccine in rhesus macaques. Vaccine 24: 4677–4687. [Medline] [CrossRef]

33. Schoenborn, J. R. and Wilson, C. B. 2007. Regulation of interferon-γ during innate and adaptive immune. Adv. Immunol. 96: 41–101. [Medline] [CrossRef]

34. Srivastava, S., Salim, N. and Robertson, M. J. 2010. Interleukin-18: biology and role in the immunotherapy of cancer. Curr. Med. Chem. 17: 3353–3357. [Medline] [CrossRef]

35. Stephenson, C. B., Welter, J., Thaker, S. R., Taylor, J., Tartaglia, J. and Paololeti, E. 1997. Canine distemper virus (CDV) infection of ferrets as a model for testing morbillivirus vaccine strategies: NYVAC- and ALVAC-based CDV recombinants protect against symptomatic infection. J. Virol. 71: 1506–1513. [Medline]

36. Sugiyama, T., Yoneda, M., Kuraishi, T., Hattori, S., Inoue, Y., Sato, H. and Kai, C. 2013. Measles virus selectively bind to signaling lymphocyte activation molecule as a novel oncolytic virus for breast cancer treatment. Gene Ther 20: 338–347. [Medline] [CrossRef]

37. Sugiyama, K., Akazawa, T., Fujimoto, M., Wijewardana, V., Mito, K., Hataya, S., Taketani, S., Komori, M., Inoue, N. and Inaba, T. 2008. Construction of an expression vector for improved secretion of canine IL-18. Vet. Immunol. Immunopathol. 126: 388–391. [Medline] [CrossRef]

38. Suter, S. E., Chein, M. B., von Messling, V., Yip, B., Cattaneo, R., Vernau, W., Madewell, B. R. and London, C. A. 2005. In vitro canine distemper virus infection of canine lymphoid cells: a prelude to oncolytic therapy for lymphoma. Clin. Cancer Res. 11: 1579–1587. [Medline] [CrossRef]

39. Trinchieri, G. and Gerosa, F. 1996. Immunoregulation by interleukin-12. J. Leukoc. Biol. 59: 505–511. [Medline]

40. Wang, X., Feng, N., Ge, J. Y., Shuai, L., Peng, L. Y., Gao, Y. W., Yang, S. T., Xia, X. Z. and Bu, Z. G. 2012. Recombinant canine distemper virus serves as bivalent live vaccine against rabies and canine distemper. Vaccine 30: 5067–5072. [Medline] [CrossRef]